Preview

Rational Pharmacotherapy in Cardiology

Advanced search

AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE

https://doi.org/10.20996/1819-6446-2017-13-1-116-123

Full Text:

Abstract

According to the World Health Organization, anxiety and depressive disorders will be the second  leading cause of disability by 2020. The review is devoted to the modern concepts of the pathophysiology of depression in patients with ischemic heart  disease (IHD) and to the possibilities of antidepressant therapy. The paper presents analysis of international and domestic researches devoted to efficiency and safety of agomelatine in patients both  with chronic IHD and with unstable angina and acute  myocardial infarction. The review also discusses different points of view, indicating the need for further  studies to evaluate the short and long term effects of antidepressants in patients with IHD in combination with anxiety and depressive disorders.

About the Authors

N. Yu. Shimohina
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Regional Inter-District Clinical Emergency Hospital named after N.S. Karpovich
Russian Federation

Natalia Yu. Shimohina – MD, PhD, Assistant, Chair of Propaedeutics of Internal Diseases and Therapy, KSMU named after Professor V. F. Voyno-Yasenetsky; Cardiologist, KRIn-D C EH named after N.S. Karpovich.

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022; Kurchatova  ul. 17,  Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660062 



M. M. Petrova
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
Russian Federation

Marina M. Petrova – MD, PhD, Professor, Head of Chair of Outpatient Therapy, Family Medicine and Healthy Lifestyle with a Course of Postgraduate Education, Vice-rector for Scientific Work, KSMU named after Professor V. F. Voyno-Yasenetsky.

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022



A. A. Savchenko
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Research Institute of Medical Problems of the North, Siberian Branch of the Russian Academy of Sciences
Russian Federation

Andrey A. Savchenko – MD, PhD, Professor, Head of the Laboratory of Molecular Cell Physiology and Pathology, Research Institute of Medical Problems of the North, Siberian Branch of the RAS; Head of Chair of Physiology named after A.T. Pshonik; KSMU named after Professor V. F. Voyno-Yasenetsky.

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022; Partizana Zheleznyaka ul. 3G, Krasnoyarsk, 660022



M. S. Chernyaeva
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
Russian Federation

Marina S. Chernyaeva – Assistant, Chair of Outpatient Therapy, Family Medicine and Healthy Lifestyle with a Course of Postgraduate Education, KSMU named after Professor V. F. Voyno-Yasenetsky. 

Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022



References

1. Kop W.J., Synowski S.J., Gottlieb S.S. Depression in heart failure: biobehavioral mechanisms. Heart Fail Clin. 2011;7(1):23-38.

2. Pizzi C., Santarella L., Manfrini O., et al. Ischemic heart disease and depression: an underestimated clinical association. G Ital Cardiol (Rome). 2013;14(7-8):526-37.

3. Hare D.L., Toukhsati S.R., Johansson P., Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35(21):1365-72.

4. Saran R.K., Puri A., Agarwal M. Depression and the heart. Indian Heart J. 2012;64(4):397-401.

5. Garganeeva N.P., Petrova M.M., Evsjukov A.A., et al. The impact of depression on the course of coronary artery disease and quality of life of patients. Klinicheskaja Medicina. 2014;92(12):30-7. (In Russ.) [Гарганеева Н.П., Петрова М.М., Евсюков А.А., Штарик С.Ю., Каскаева Д.С. Влияние депрессии на особенности течения ишемической болезни и качество жизни пациентов. Клиническая Медицина. 2014;92(12):30-7].

6. Chalmers J.A., Quintana D.S., Abbott M.J., Kemp A.H. Anxiety Disorders are Associated with Reduced Heart Rate Variability: A Meta-Analysis. Front Psychiatry. 2014;5:80.

7. Smith P.J., Blumenthal J.A. Psychiatric and behavioral aspects of cardiovascular disease: epidemiology, mechanisms, and treatment. Rev Esp Cardiol. 2011;64(10):924-33.

8. Celano C.M., Huffman J.C. Depression and cardiac disease: a review. Cardiol Rev. 2011;19(3):130-42.

9. Smulevich A.B. Depression in cardiovascular diseases. Psihicheskie Rasstrojstva v Obshhej Medicine. 2013;4:4-9. (In Russ.) [Смулевич А.Б. Депрессии при сердечно-сосудистых заболеваниях. Психические Расстройства в Общей Медицине. 2013;4:4-9].

10. Ford D.E., Mead L.A., Chang P.P., et al. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med. 1998;158(13):1422-6.

11. Freedland K.E., Carney R.M., Rich M.W. Effect of depression on prognosis in heart failure. Heart Fail Clin. 2011;7(1):11-21.

12. Smeijers L., Mostofsky E., Tofler G.H., et al. Association between high levels of physical exertion, anger, and anxiety immediately before myocardial infarction with mortality during 10-year follow-up. J Am Coll Cardiol. 2015;66(9):1083-4.

13. Wrenn K.C., Mostofsky E., Tofler G.H., et al. Anxiety, anger, and mortality risk among survivors of myocardial infarction. Am J Med. 2013;126(12):1107-13.

14. Roest A.M., Zuidersma M., de Jonge P. Myocardial infarction and generalised anxiety disorder: 10year follow-up. Br J Psychiatry. 2012;200(4):324-9.

15. Huffman J.C. Review: depression after myocardial infarction is associated with increased risk of all-cause mortality and cardiovascular events. Evid Based Ment Health. 2013;16(4):110.

16. Carney R.M., Freedland K.E. Depression and heart rate variability in patients with coronary heart disease. Cleve Clin J Med. 2009;76(Suppl 2):S13-7.

17. Mazereeuw G., Herrmann N., Bennett S.A., et al. Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration. Neurosci Biobehav Rev. 2013;37(8):1611-21.

18. Sanner J.E., Frazier L. The role of serotonin in depression and clotting in the coronary artery disease population. J Cardiovasc Nurs. 2011;26(5):423-9.

19. Serrano C.V. Jr, Setani K.T., Sakamoto E., et al. Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications. Vasc Health Risk Manag. 2011;7:159-64.

20. Blumenthal J.A. New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. Cleve Clin J Med. 2011;78(Suppl 1):S35-S43.

21. Mavrides N., Nemeroff C. Treatment of depression in cardiovascular disease. Depress Anxiety. 2013;30(4):328-41.

22. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2-8.

23. Ha J.H., Wong C.K. Pharmacologic treatment of depression in patients with myocardial infarction. J Geriatr Cardiol. 2011;8(2):121-6.

24. Rejai S., Giardino N.D., Krishnan S., et al. Quality of life and baseline characteristics associated with depressive symptoms among patients with heart disease. Clin Epidemiol. 2012;4:181-6.

25. Lange-Asschenfeldt C., Lederbogen F. Antidepressant therapy in coronary artery disease. Nervenarzt. 2011;82(5):657-64.

26. Oh S.W., Kim J., Myung S.K., et al. Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies. Br J Clin Pharmacol. 2014;78(4):727-37.

27. Kimmel S.E., Schelleman H., Berlin J.A., et al. The effect of selective serotonin reuptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol. 2011;72(3):514-7.

28. Taylor C.B., Youngblood M.E., Catellier D., et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62(7):792-8.

29. Von Ruden A.E., Adson D.E., Kotlyar M. Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality. J Cardiovasc Pharmacol Ther. 2008;13(1):32-40.

30. Davidson K.W., Rieckmann N., Clemow L., et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170(7):600-8.

31. Elderon L., Whooley M.A. Depression and cardiovascular disease. Prog Cardiovasc Dis. 2013;55(6):511-23.

32. Kasper S., Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 2009;10(2):117-26.

33. Smeraldi E., Delmonte D. Agomelatine in depression. Expert Opin Drug Saf. 2013;12(6):873-80.

34. Manikandan S. Agomelatine: A novel melatonergic antidepressant. J Pharmacol Pharmacother. 2010;1(2):122-3.

35. Ushkalova A., Ushkalova E. Agomelatine (agomelatine) antidepressant with a novel mechanism of action. Vrach. 2011;5:41-4. (In Russ.) [Ушкалова А., Ушкалова Е. Агомелатин (вальдоксан) антидепрессант с новым механизмом действия. Врач. 2011;5:41-4].

36. Srinivasan V., De Berardis D., Shillcutt S.D., Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012;21(10):1503-22.

37. Green B. Focus on agomelatine. Curr Med Res Opin. 2011;27(4):745-9.

38. Stein D.J., Picarel-Blanchot F., Kennedy S.H. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013;28(2):151-9.

39. Pribytkov A.A., Panova N.B., Popova Ju.V., Emcov K.G. The efficacy of agomelatine in depressive disorders with anxiety. Zhurnal Nevrologii i Psihiatrii im. C.C. Korsakova. 2013;113(11-2):53-8. (In Russ.) [Прибытков А.А., Панова Н.Б., Попова Ю.В., Емцов К.Г. Эффективность агомелатина при депрессивных расстройствах с тревогой. Журнал неврологии и психиатрии им. C.C. Корсакова. 2013;113(11-2):53-8].

40. Gavrilova S.I., Kolyhalov I.V., Ponomareva E.V., Selezneva N.D. Experience of clinical application of agomelatine for the treatment of depression in elderly patients in outpatient practice. Zhurnal Nevrologii i Psihiatrii im. C.C. Korsakova. 2014;114(9):43-8. (In Russ.) [Гаврилова С.И., Колыхалов И.В., Пономарева Е.В., Селезнева Н.Д. Опыт клинического применения агомелатина для лечения депрессии у пожилых больных в амбулаторной практике. Журнал Неврологии и Психиатрии им. C.C. Корсакова. 2014;114(9):43-8].

41. Lôo H., Daléry J., Macher J.P., Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders. Encephale. 2003;29(2):165-71.

42. Singh S.P., Singh V., Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012;15(3):417-28.

43. Koesters M., Guaiana G., Cipriani A., et al. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. British Journal of Psychiatry. 2013;203:179-87.

44. Huang K.L., Lu W.C., Wang Y.Y., et al. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. Australian and New Zealand Journal of Psychiatry. 2014;48(7):663-71.

45. Taylor D., Sparshatt A., Varma S., Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g2496.

46. Srinivasan V., Zakaria R., Othman Z., et al. Agomelatine in depressive disorders: its novel mechanisms of action. Neuropsychiatry Clin Neurosci. 2012;24(3):290-308.

47. Orudzhev N.J., Poplavskaja O.V. Melatonergic antidepressant agomelatine (agomelatine) in the treatment of depressive disorders. Lekarstvennyj Vestnik. 2014;8(2):33-6. (In Russ.) [Оруджев Н.Я., Поплавская О.В. Мелатонинергический антидепрессант агомелатин (вальдоксан) в терапии депрессивных расстройств. Лекарственный Вестник. 2014;8(2):33-6].

48. Laudon M., Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014;15(9):15924-50.

49. De Berardis D., Di Iorio G., Acciavatti T., et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets. 2011;10(1):119-32.

50. Racagni G., Riva M.A., Molteni R., et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry. 2011;12(8):574-87.

51. De Bodinat C., Guardiola-Lemaitre B., Mocaër E., et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9.(8):628-42.

52. Demyttenaere K. Agomelatine in treating generalized anxiety disorder. Expert Opin Investig Drugs. 2014;23(6):857-64.

53. Chutko L.S., Rozhkova A.V., Sidorenko V.A., et al. Generalized anxiety disorder: psychosomatic aspects and approaches to treatment. Zhurnal Nevrologii i Psihiatrii im. C.C. Korsakova. 2012;112(1):40-4. (In Russ.) [Чутко Л.С., Рожкова А.В., Сидоренко В.А., Сурушкина С.Ю., Турсунова К.Б. Генерализованное тревожное расстройство: психосоматические аспекты и подходы к лечению. Журнал Неврологии и Психиатрии им. C.C. Корсакова. 2012;112(1):40-4].

54. Abejuela H.R., Osser D.N. The psychopharmacology algorithm project at the Harvard south shore program: an algorithm for generalized anxiety disorder. Harv Rev Psychiatry. 2016;24(4):243-56.

55. Рoponina Т.М., Рoponina Yu.S., Gunderina K.I., Markov V.A. Status of mental status and the possibility of its correction in patients with acute coronary syndrome associated with anxiety and depressive disorders. Кompleksnye Problemy Serdechno-sosudistyh Zabolevanij. 2013;3:81-2. (In Russ.) [Попонина Т.М., Попонина Ю.С., Гундерина К.И., Марков В.А. Состояние психического статуса и возможности его коррекции у больных с острым коронарным синдромом, ассоциированным с тревожно-депрессивными расстройствами. Комплексные Проблемы Сердечно-сосудистых Заболеваний. 2013;3:81-2].

56. Gajfullina R., Kim Z., Strel'cova L., et al. Agomelatine in the complex treatment of patients with coronary artery disease. Vrach. 2012;9:78-82. (In Russ.) [Гайфуллина Р., Ким З., Стрельцова Л., Мустафина Э., Хаятова З., Павлова М. Вальдоксан в комплексном лечении больных ИБС. Врач. 2012;9:78-82].

57. Goodwin G.M., Boyer P., Emsley R., et al. Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. Int Clin Psychopharmacol. 2013;28(1):20-8.

58. Mihajlovicheva A.I., Janushko P.S. Applications of agomelatine in the treatment of anxiety and depressive disorders in patients with unstable angina. Bjulleten' Medicinskih Internet-konferencij. 2014;4(4):401-4. (In Russ.) [Михайловичева А.И., Янушко П.С. Возможности применения агомелатина в терапии тревожно-депрессивных расстройств у пациентов с нестабильной стенокардией. Бюллетень Медицинских Интернет-конференций. 2014;4(4):401-4].

59. Smeraldi E., Delmonte D. Agomelatine in depression. Expert Opin Drug Saf. 2013;12(6):873-80.

60. Kirpichenko A.A. The newest antidepressant agomelatine in the treatment of affective spectrum disorders. Psihiatrija, Psihoterapija i Klinicheskaja Psihologija. 2014;2(16):87-91. (In Russ.) [Кирпиченко А.А. Новейший антидепрессант агомелатин в лечении расстройств аффективного спектра. Психиатрия, Психотерапия и Клиническая Психология. 2014;2(16):87-91].

61. Stacenko M.E., Shilina N.N., Turkina S.V. Efficacy of agomelatine in the recovery phase of myocardial infarction in patients with type 2 diabetes, and anxiety and depressive disorders. Psihiatrija i Psihofarmakoterapija. 2012;14(6):8-13. (In Russ.) [Стаценко М.Е., Шилина Н.Н., Туркина С.В. Эффективность применения вальдоксана в восстановительном периоде инфаркта миокарда у пациентов с сахарным диабетом типа 2 и тревожно-депрессивными расстройствами. Психиатрия и Психофармакотерапия. 2012;14(6):8-13].

62. Medvedev V.E., Epifanov A.V. An innovative method of treatment of depression in patients with coronary heart disease. Obozrenie Psihiatrii i Medicinskoj Psihologii im. V.M. Behtereva. 2010;3:31-6. (In Russ.) [Медведев В.Э., Епифанов А.В. Инновационный метод терапии депрессий у пациентов с ишемической болезнью сердца. Обозрение Психиатрии и Медицинской Психологии им. В.М. Бехтерева. 2010;3:31-6].

63. Heun R., Ahokas A., Boyer P., et al; Agomelatine Study Group. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry. 2013;74(6):587-94.


For citation:


Shimohina N.Y., Petrova M.M., Savchenko A.A., Chernyaeva M.S. AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE. Rational Pharmacotherapy in Cardiology. 2017;13(1):116-123. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-1-116-123

Views: 397


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)